Neostigmine is always administered in conjunction with glycopyrrolate and, until now, its administration has required two syringes. as single, active ingredient drug products. 'With two medications in one ready-to-use syringe, PREVDUO ™ reduces complexity and increases efficiency for hospitals and healthcare providers.'īoth neostigmine methylsulfate and glycopyrrolate have been approved in the U.S. 'This is the latest way we're addressing operational and clinical challenges in order to support patient care,' said Scott Sims, Senior Vice President and General Manager, Injectable Solutions & Generics at Endo.
